XPANCEO

XPANCEO is a Smart Contact Lenses company founded in 2021 and based in Dubai, United Arab Emirates. It has raised $290M in total funding, most recently a Series A in 2025 at a $1.4B valuation.

Building smart contact lenses with embedded XR displays and continuous health monitoring; raised $250M Series A in 2025 at a $1.35B valuation.

The most-funded contact-lens-form-factor spatial computing play; only unicorn in the non-headset spatial category.

xpanceo.com Smart Contact Lenses

United Arab Emiratesprivate

At a glance

Total raised

$290M

last round series a

Headcount

51-200

approximate · public range

Headquarters

Dubai

United Arab Emirates

Founded

2021

5 years active

Status

Private

Smart Contact Lenses

Latest valuation

Funding history

Total raised

$290M

Rounds tracked

Latest stage

Series A

Latest valuation

$1.4B

Date	Stage	Amount	Valuation	Lead investors
Jul 8, 2025	Series A	$250M	$1.4B	Opportunity Venture (Asia)
Oct 16, 2023	Seed	$40M	—

Products

AR Vision Smart Contact Lens
XPANCEO's primary product is an invisible, weightless smart contact lens designed as the ultimate computing platform for AI-powered XR. The lens integrates a proprietary microdisplay with a 30° field of view, delivering augmented reality directly to the wearer's vision. It features ultra-low power consumption (1-3 µW), making it up to 300 times more efficient than conventional AR headsets. The device seamlessly merges the real and digital worlds, enabling users to experience applications, content, and digital interfaces without separate devices.
Smart Contact Lens for Health Monitoring
XPANCEO's health-focused smart lens variant integrates advanced biosensing technology to continuously monitor vital health metrics in real-time. The lens incorporates tear-fluid biosensors capable of detecting biomarkers including glucose levels, cortisol, and key vitamins. It also features intraocular pressure (IOP) tracking with reportedly 50% greater precision than existing solutions for non-invasive glaucoma monitoring. This product addresses critical healthcare needs by enabling personalized dosing adjustments via tear diagnostics and early detection of diseases like diabetes and glaucoma.
Smart Contact Lens for Medicine Monitoring
This specialized variant enables non-invasive detection of medication activity in the body through tear-based analysis. The lens uses custom-developed gold nanoparticles—biocompatible structures roughly 1,000 times thinner than human hair—to achieve the exceptional sensitivity needed for accurate biochemical measurements. This product is particularly valuable for complex therapies with pronounced side effects such as cancer and thrombosis treatments, where real-time medication monitoring can optimize patient outcomes and safety.
Night Vision and Color Correction Smart Lens
XPANCEO has developed prototype smart lenses incorporating nanoparticle engineering to enable enhanced low-light vision capabilities and color blindness compensation. The night vision variant allows users to see clearly in dark or low-light environments, beneficial for military, security, emergency services, and aerospace applications. The color correction lens helps users with color blindness experience more accurate color perception, demonstrating XPANCEO's commitment to inclusive computing that enhances human capability across diverse use cases and populations.

XPANCEO

At a glance

Funding history

In the news

While Everyone Fights Over AR Glasses, Two Companies Are Building the Display for What Comes Next: Contact Lenses.

Smart Contact Lenses Move Closer to Reality as XPANCEO Expands JBD Display Partnership

Watch

Leadership

Products

AR Vision Smart Contact Lens

Smart Contact Lens for Health Monitoring

Smart Contact Lens for Medicine Monitoring

Night Vision and Color Correction Smart Lens

Compare XPANCEO with